Table of Contents Table of Contents
Previous Page  620 / 1726 Next Page
Information
Show Menu
Previous Page 620 / 1726 Next Page
Page Background

Stage I intermediate risk (n=714):

grade 1 or 2 with

≥50% invasion

grade 2 or 3 with <50% invasion

TAH-BSO without lymphadenectomy

R

pelvic radiotherapy

no further treatment

Creutzberg et al, Lancet 2000

PORTEC-1 trial (1990-1997)

46 Gy / 23# / 5 wks